ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1054

Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

David Liew1, Aurora Poon1, Christopher McMaster2, Russell Buchanan1, Victor Yang1, Andrew Scott1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Pascoe Vale South, Australia, 3Austin Health, Malvern East, Australia

Meeting: ACR Convergence 2023

Keywords: Drug toxicity, Nuclear Medicine, Oncology, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to comprise a small subset, distinct from other irAEs. ICI-PMR also appear distinct from classical PMR, given they are temporally related to ICI exposure and occur at far greater incidence than expected for classical PMR alone. ICI-PMR have previously been associated with findings consistent with inflammatory morphological change on [18F]Fluorodeoxyglucose-PET/CT (FDG-PET/CT), a modality used for cancer staging. Classical PMR also has highly accurate diagnostic scintigraphic features on FDG-PET/CT. It is not known to what extent the detailed inflammatory morphological changes in ICI-PMR correlate with those in classical PMR.

Methods: A comparison was made of FDG-PET/CT images from active ICI-PMR and active classical PMR patients. Images in ICI-PMR patients were obtained from a retrospective repository of routine care FDG-PET/CT incidentally obtained for cancer staging. Images were selected where the time of image acquisition correlated with ICI-PMR active disease. Both diagnosis and disease activity assessment for ICI-PMR patients were determined by a rheumatologist expert in irAEs, without reference to FDG-PET/CT. Patients with clinically apparent inflammatory arthritis were excluded. Images in classical PMR were obtained from a prospective research cohort, after diagnosis and prior to glucocorticoid therapy. All patients met the 2012 ACR/EULAR PMR Classification Criteria. Seventeen sites specific to classical PMR FDG-PET/CT assessment were assessed by a nuclear medicine physician expert in assessment of PET/CT for PMR, blinded to clinical context, and were combined into seven regional sites for comparison.

Results: This analysis captured nine patients with ICI-PMR who had an incidental FDG-PET/CT when their ICI-PMR was active. The median age was 79 (69-85). The ICI indication was melanoma in 5 patients, and non-small cell lung cancer in 4 patients. The ICI agent was nivolumab in 4, pembrolizumab in 4, and durvalumab in 1; only one was receiving combination therapy with ipilimumab. There were 31 patients in the classical PMR cohort. While the overall intensity of uptake was lower in the ICI-PMR cohort, notable morphological similarities existed between both sets of patients (Table 1). Of the seven sites, shoulder capsule and ischial tuberosity ranked in the top three for both groups. For both ICI-PMR and classical PMR, intraarticular uptake at shoulder and hip joints was lower than periarticular sites classical for polymyalgia rheumatica.

Conclusion: ICI-PMR and classical PMR demonstrate similar patterns of scintigraphic uptake on FDG-PET/CT. This close similarity in inflammatory morphological change implies that classical PMR properties might inform ICI-PMR research, and that insights from ICI-PMR might prove useful for classical PMR research, as a model of induced disease.

Supporting image 1

Table 1:
Scintigraphic comparison (comparison of PMR and irAE cohorts performed by ranking
7 sites in order of average SUVmax – 5 classical PMR sites and 2 intra-articular sites)


Disclosures: D. Liew: None; A. Poon: None; C. McMaster: None; R. Buchanan: None; V. Yang: None; A. Scott: None; C. Owen: AbbVie/Abbott, 1, 6, Janssen, 6, Novartis, 6.

To cite this abstract in AMA style:

Liew D, Poon A, McMaster C, Buchanan R, Yang V, Scott A, Owen C. Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/immune-checkpoint-inhibitor-induced-polymyalgia-rheumatica-demonstrates-a-similar-scintigraphic-appearance-to-classical-polymyalgia-rheumatica-on-18f-fluorodeoxyglucose-pet-ct/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-checkpoint-inhibitor-induced-polymyalgia-rheumatica-demonstrates-a-similar-scintigraphic-appearance-to-classical-polymyalgia-rheumatica-on-18f-fluorodeoxyglucose-pet-ct/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology